CD274 and metastatic melanoma: Our findings provide a pre-clinical proof-of-concept with novel mechanisms and translational relevance for a new avenue of antibody targeting sMIC to enhance PD1/PDL1 immune checkpoint blockade therapy for metastatic melanoma patients.